Cargando…

Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy

BACKGROUND: Breast carcinoma is the commonest cancer among UAE population and the most common cancer among females. Examination of the 5′ promoter regions of trefoil factor 3 (TFF3) gene has identified putative estrogen and progesterone receptor–DNA binding domains as direct response elements to est...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Salam, Suhail, Sudhadevi, Manjusha, Awwad, Aktham, Al Bashir, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371459/
https://www.ncbi.nlm.nih.gov/pubmed/30744593
http://dx.doi.org/10.1186/s12885-019-5316-y
_version_ 1783394546928844800
author Al-Salam, Suhail
Sudhadevi, Manjusha
Awwad, Aktham
Al Bashir, Mohamed
author_facet Al-Salam, Suhail
Sudhadevi, Manjusha
Awwad, Aktham
Al Bashir, Mohamed
author_sort Al-Salam, Suhail
collection PubMed
description BACKGROUND: Breast carcinoma is the commonest cancer among UAE population and the most common cancer among females. Examination of the 5′ promoter regions of trefoil factor 3 (TFF3) gene has identified putative estrogen and progesterone receptor–DNA binding domains as direct response elements to estrogen and progesterone that are linked to breast functions or steroid regulation. The study was designed to determine the role of TFF3 in breast cancer chemoresistance with the aim of establishing TFF3 expression as a biomarker for drug resistance. METHODS: In total, 133 cases of breast carcinoma treated with neo-adjuvant therapy were collected. Tissue samples from pre-neoadjuvant therapy as well as tissues from post-neo-adjuvant therapy of those cases were collected and stained with immunohistochemistry for TFF3, Bcl2, BAX, cleaved caspase-3, AKT-1, NF kappa B and Ki-67. RESULTS: There was increased expression of TFF3 in residual invasive carcinoma cells. There was a significant correlation between the expression of TFF3 in breast carcinoma cells and response to neoadjuvant chemotherapy (p = 0.0165). There was significant co-expression of TFF3 with AKT1 (p = 0.0365), BCl2 (p = 0.0152), and NF Kappa-B (p = 0.0243) in breast carcinoma cases with residual carcinoma following neoadjuvant therapy which support the role of TFF3 in chemoresistance. CONCLUSION: The expression of TFF3 is significantly associated with residual breast carcinoma following neoadjuvant chemotherapy suggesting its expression is associated with increased resistance to chemotherapy. This is supported by its co-expression with antiapoptotic proteins; BCl2, AKT1 and NF Kappa-B in residual breast carcinoma cells and very low proliferating index and apoptotic bodies in residual tumors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5316-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6371459
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63714592019-02-21 Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy Al-Salam, Suhail Sudhadevi, Manjusha Awwad, Aktham Al Bashir, Mohamed BMC Cancer Research Article BACKGROUND: Breast carcinoma is the commonest cancer among UAE population and the most common cancer among females. Examination of the 5′ promoter regions of trefoil factor 3 (TFF3) gene has identified putative estrogen and progesterone receptor–DNA binding domains as direct response elements to estrogen and progesterone that are linked to breast functions or steroid regulation. The study was designed to determine the role of TFF3 in breast cancer chemoresistance with the aim of establishing TFF3 expression as a biomarker for drug resistance. METHODS: In total, 133 cases of breast carcinoma treated with neo-adjuvant therapy were collected. Tissue samples from pre-neoadjuvant therapy as well as tissues from post-neo-adjuvant therapy of those cases were collected and stained with immunohistochemistry for TFF3, Bcl2, BAX, cleaved caspase-3, AKT-1, NF kappa B and Ki-67. RESULTS: There was increased expression of TFF3 in residual invasive carcinoma cells. There was a significant correlation between the expression of TFF3 in breast carcinoma cells and response to neoadjuvant chemotherapy (p = 0.0165). There was significant co-expression of TFF3 with AKT1 (p = 0.0365), BCl2 (p = 0.0152), and NF Kappa-B (p = 0.0243) in breast carcinoma cases with residual carcinoma following neoadjuvant therapy which support the role of TFF3 in chemoresistance. CONCLUSION: The expression of TFF3 is significantly associated with residual breast carcinoma following neoadjuvant chemotherapy suggesting its expression is associated with increased resistance to chemotherapy. This is supported by its co-expression with antiapoptotic proteins; BCl2, AKT1 and NF Kappa-B in residual breast carcinoma cells and very low proliferating index and apoptotic bodies in residual tumors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5316-y) contains supplementary material, which is available to authorized users. BioMed Central 2019-02-11 /pmc/articles/PMC6371459/ /pubmed/30744593 http://dx.doi.org/10.1186/s12885-019-5316-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Al-Salam, Suhail
Sudhadevi, Manjusha
Awwad, Aktham
Al Bashir, Mohamed
Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
title Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
title_full Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
title_fullStr Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
title_full_unstemmed Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
title_short Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
title_sort trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371459/
https://www.ncbi.nlm.nih.gov/pubmed/30744593
http://dx.doi.org/10.1186/s12885-019-5316-y
work_keys_str_mv AT alsalamsuhail trefoilfactorspeptide3isassociatedwithresidualinvasivebreastcarcinomafollowingneoadjuvantchemotherapy
AT sudhadevimanjusha trefoilfactorspeptide3isassociatedwithresidualinvasivebreastcarcinomafollowingneoadjuvantchemotherapy
AT awwadaktham trefoilfactorspeptide3isassociatedwithresidualinvasivebreastcarcinomafollowingneoadjuvantchemotherapy
AT albashirmohamed trefoilfactorspeptide3isassociatedwithresidualinvasivebreastcarcinomafollowingneoadjuvantchemotherapy